Status:

COMPLETED

Postmenopausal Women Estrogen and Progesterone Infusion

Lead Sponsor:

Massachusetts General Hospital

Collaborating Sponsors:

National Institute on Aging (NIA)

Conditions:

Postmenopause

Aging

Eligibility:

FEMALE

45-80 years

Phase:

PHASE1

PHASE2

Brief Summary

The purpose of the study is to study the effects of aging, estrogen and progesterone on the brain. Specifically, we want to look at how the hypothalamus and pituitary (two small glands in the brain) r...

Detailed Description

The transition to menopause is characterized by a decline in the numbers of functional ovarian follicles followed by a decrease in levels of inhibin A and B and complex changes in estradiol, which inc...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • postmenopausal women young (age 45-55) or old (age 70-80) History of natural menopause defined by the absence of menses for at least 12 months (or history of surgical menopause defined as bilateral oophorectomy) Normal TSH, PRL and CBC, and Factor V activity Normal BUN and Creatinine (\< 2 times the upper limit of normal) BMI between 18 to 30 kg/m2 An increased FSH measured at the screening visit will be consistent with menopause. If the initial determination is low, a repeat sample may be drawn.
  • Exclusion criteria:
  • Hormonal medication or herbal supplements and/or over the counter menopause therapy in the 2 months prior to study Any absolute contraindications to the use of physiologic replacement doses of estrogen and/or progesterone History of coronary artery disease Medications thought to act centrally on the GnRH pulse generator History of breast cancer or blood clots Smoking more than 10 cigarettes/day Prior history of allergic reaction to any dyes used with x-rays or scans and/ or any other contraindications to PET scans No metal implants, pacemakers, aneurysm clips, implanted hearing aids and/or any other contraindications to MRI scan

Exclusion

    Key Trial Info

    Start Date :

    November 1 2000

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    August 22 2015

    Estimated Enrollment :

    20 Patients enrolled

    Trial Details

    Trial ID

    NCT00455741

    Start Date

    November 1 2000

    End Date

    August 22 2015

    Last Update

    May 18 2018

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Massachusetts General Hospital

    Boston, Massachusetts, United States, 02114